Narayana Hrudayalaya Q1 Consolidated Revenue Rises To 26.84b Rupees Versus 15.07b YoY

Market snapshot: Narayana Hrudayalaya Limited posted a robust top-line performance for Q1 FY27, with consolidated operating revenue surging to ₹2,683.63 crore. The growth was backed by strong domestic operations and the full-quarter integration of its UK business. However, operating margins faced compression, with EBITDA margin declining to 18.82% due to rising doctor professional fees and integration costs, while consolidated net profit grew modestly to ₹207.27 crore.

Data Snapshot

• Consolidated operating revenue grew by 78.04% year-on-year to ₹2,683.63 crore in Q1 FY27.
• Consolidated EBITDA stood at ₹505.18 crore, marking a 40.04% year-on-year increase.
• Consolidated Net Profit (PAT) grew by 5.72% year-on-year to ₹207.27 crore.
• The consolidated EBITDA margin stood at 18.82%, compressing from 23.93% in the prior year quarter.

What's Changed

• Consolidated operating revenue grew to ₹2,683.63 crore in Q1 FY27 from ₹1,507.27 crore in Q1 FY26 (derived: ≈78.04% YoY growth).
• Consolidated net profit (PAT) rose to ₹207.27 crore in Q1 FY27 compared to ₹196.05 crore in Q1 FY26 (derived: ≈5.72% YoY growth).
• Consolidated EBITDA margin compressed to 18.82% in Q1 FY27 compared to 23.93% in Q1 FY26 (derived: decline of 511 bps).

Key Takeaways

• Top-line expansion was driven by a full-quarter consolidation of the UK business (contributing ₹825.7 crore) alongside steady growth in domestic operations.
• India hospital operations reported 17.0% YoY growth to ₹1,324.7 crore, indicating resilient domestic healthcare demand.
• The health insurance segment reported a widening quarterly loss of ₹62.5 crore in Q1 FY27 compared to a loss of ₹24 crore in Q1 FY26, acting as a major operational drag.
• Professional fees paid to doctors rose to ₹327.01 crore, while finance costs jumped 92.0% YoY to ₹86.8 crore due to acquisition debt obligations.
• Net debt-to-equity remains highly manageable at 0.42x, with net debt ending the quarter at ₹1,967.1 crore.

SAHI Perspective

Narayana Hrudayalaya is undergoing a rapid transition phase. While the core domestic business remains highly resilient with 16.3% revenue growth on a standalone basis, the consolidated profitability highlights the temporary headwinds of integrating international acquisitions. The dilution in EBITDA margins to 18.82% and widening health insurance segment losses are active pressure points. However, the group’s strong clinical franchise and disciplined leverage position it well to absorb these integration costs over the medium term.

Market Implications

The near-term performance of the stock is likely to reflect margin concerns. While top-line growth is highly positive, investors will wait for operational synergies from the UK business and breakeven milestones in the domestic insurance division. Capex execution will also remain in focus as the company holds its 26th AGM to seek approvals for a ₹1,500 crore debt-raising capacity.

Trading Signals

Market Bias: Neutral

Strong top-line growth is offset by a 511 bps contraction in consolidated EBITDA margin and widening losses in the health insurance segment, indicating near-term consolidation.

Overweight: Healthcare Services, Hospitals

Underweight: Health Insurance

Trigger Factors:

• Margin recovery post-UK integration
• Reduction in domestic health insurance segment losses
• Capex deployment under the proposed ₹1,500 crore debt room

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian healthcare and hospital space continues to see high structural demand with bed capacities being scaled up. However, capital expenditures and international acquisitions are temporarily diluting immediate returns. Narayana Hrudayalaya's focus remains on maintaining high clinical efficiencies (Average Revenue Per Occupied Bed of ₹1.92 crore in Q1 FY27 vs ₹1.76 crore YoY) while absorbing integration costs.

Key Risks to Watch

• EBITDA margin compression from integration of lower-margin international operations.
• Rising finance costs due to foreign currency denominated debt.
• Continued losses in the health insurance segment acting as a drag on bottom-line.

Recent Developments

On July 23, 2026, the company dispatched its 26th AGM notice and FY26 annual report, showing FY26 consolidated revenue up 44.01% YoY to ₹7,896.04 crore and net profit of ₹810.50 crore. On July 28, 2026, the company announced its Q1 FY27 results investor call scheduled for August 3, 2026.

Closing Insight

Narayana Hrudayalaya's scaling strategy has successfully delivered impressive top-line growth, but operating metrics are now in a consolidation phase. Resolving margin headwinds from the UK business and insurance losses will determine if the hospital major can translate its massive scale into matching bottom-line returns.

High Performance Trading with SAHI.